SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ARB IOT Group Ltd. is a holding company that engages in the provision of solutions for the integration of IoT systems and devices. It operates through the Internet of Things and Investment Holding and Others segments. The company was founded on March 1, 2022 and is headquartered in Singapore.

ARB IOT Group Ltd

ARBB is trending as traders discuss its low float and potential for a significant breakout, drawing comparisons to other low-float stocks. Community members highlight the possibility of a short squeeze and anticipation for news catalysts, driving speculation about a potential run to higher price levels. Traders are closely monitoring key price levels as potential triggers for further upward momentum.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences ($GLSI) is trending due to positive buzz surrounding its FLAMINGO-01 trial and anticipation of potential news. The community highlights a preliminary analysis showing a significant recurrence rate reduction, fueling excitement. Discussions also revolve around the high short borrow rate and potential for a short squeeze, with some expecting major announcements soon.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending amid speculation around potential cannabis rescheduling, driven by reports of executive action and Supreme Court involvement. Community members are weighing the potential impacts on the sector, discussing possible rallies and short squeezes while considering potential volatility and the long-term implications for cannabis businesses. The focus remains on upcoming announcements and their effects on market dynamics.

nLIGHT, Inc. engages in the provision of semiconductor and fiber lasers for aerospace and defense, industrial, and microfabrication applications. It operates through the Laser Products and Advanced Development segments. The Laser Products segment designs, manufactures, and sells a range of semiconductor lasers and fiber lasers that are typically integrated into laser systems or manufacturing tools built by customers. The Advanced Development segment focuses on research, design, and prototyping of next-generation laser technologies, leveraging expertise in laser technology, development, beam control, and advanced optics. The company was founded by Scott H. Keeney, Mark DeVito, and Jason Farmer in June 2000 and is headquartered in Camas, WA.

nLIGHT Inc

nLIGHT ($LASR) is trending as chatter around defense contracts and the "Golden Dome" project heats up. The community speculates about potential benefits from increased defense spending and upcoming contracts. Some are also discussing the potential for a short squeeze.

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

KYTX is trending as investors await Phase 2 trial results for KYV-101 in stiff person syndrome, expected imminently, with some speculating about positive news catalysts before year-end. Community chatter highlights the potential for a significant breakout, noting institutional backing and a potentially undervalued stock price relative to cash on hand. Some analysts have recently updated their rating for KYTX to Overweight.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarin is trending as the community discusses the potential for a strategic transaction, fueled by the recent COO promotion and Barclays remaining as advisor.  Discussion is also focused on the upcoming earnings report and potential catalysts such as China NRDL inclusion.  Community members are analyzing the company's financial health, revenue potential, and patent landscape.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

ARM is trending as investors assess its potential in the AI sector following a recent partnership announcement; the community is actively discussing the implications of this collaboration and its impact on ARM's growth trajectory. Recent analyst ratings and price target adjustments are also fueling the conversation around the stock's valuation. However, some traders note that ARM's stock movement can be manipulated due to its low float, making it a risky play.

Argo Blockchain Plc operates as a blockchain technology company focused on large-scale mining of Bitcoin and other cryptocurrencies. It mines using purpose-built computers to solve cryptographic algorithms in the blockchain in exchange for rewards and fees denominated in the native token of that blockchain network. The company was founded in 2017 and is headquartered in London, the United Kingdom.

Argo Blockchain Plc - ADR

Argo Blockchain Plc

ARBK is trending due to a potential short squeeze amplified by its nano float and recent reverse stock split, attracting both bullish and bearish sentiments. Traders are actively discussing its high volatility, low price, and the possibility of a dead cat bounce, with some comparing it to other high-potential squeeze candidates. The broader context includes its restructuring to avoid insolvency, delisting from the London Stock Exchange, and correlation with Bitcoin's movements, all contributing to the intense community debate.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is trending amid discussions around a potential acquisition of cybersecurity firm Armis, with community members weighing the strategic implications of expanding its security offerings. Keybanc's recent underweight rating is also contributing to the conversation. Additionally, the stock's technical indicators, including RSI and moving averages, are being analyzed for potential trade opportunities.

Compass, Inc. engages in the provision of an online real estate platform. Its platform provides an integrated suite of software for customer relationship management, marketing, client service, operations and other critical functionality, as well as brokerage services and adjacent services. The company was founded by Ori Allon and Robert Reffkin in 2012 and is headquartered in New York, NY.

Compass Inc - Ordinary Shares - Class A

COMP is trending as investors discuss its potential for growth in the mid-tier and luxury real estate markets, particularly with global expansion and strategic acquisitions being key talking points. Bullish sentiment is emerging, with some anticipating a breakout above the $11 resistance level, although overbought conditions indicated by high RSI values and recent analyst rating changes warrant caution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Achieve Life Sciences (NASDAQ:ACHV) Share Price Passes Above Two Hundred Day Moving Average - Here's What Happened

Achieve Life Sciences (NASDAQ:ACHV) Share Price Crosses Above 200 Day Moving Average - Time to Sell...

Stonepine Capital Management LLC Takes Position in Achieve Life Sciences, Inc. $ACHV

Stonepine Capital Management LLC acquired a new stake in shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) in the 2nd quarter, according to the company in its most recent disclosure...

Achieve Life Sciences, Inc. (NASDAQ:ACHV) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report) have been assigned an average rating of "Moderate Buy" from the five brokerages that are presently covering the firm, Marketbeat...

Highbridge Capital Management LLC Acquires New Stake in Achieve Life Sciences, Inc. $ACHV

Highbridge Capital Management LLC acquired a new stake in shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) in the second quarter, according to the company in its most recent filing...

What is Zacks Small Cap's Estimate for ACHV FY2025 Earnings?

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) - Equities researchers at Zacks Small Cap cut their FY2025 earnings per share estimates for Achieve Life Sciences in a report issued on Monday...

Achieve Life Sciences, Inc. $ACHV Shares Bought by Simplify Asset Management Inc.

Simplify Asset Management Inc. boosted its stake in Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) by 443.7% in the second quarter, according to its most recent filing with the Securities...

Achieve Life Sciences (NASDAQ:ACHV) Posts Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, missing the...

Shares of Achieve Life Sciences, Inc. (ACHV) soared 32% on Friday afternoon after the company said that the U.S. Food and Drug Administration (FDA) awarded the company a Commissioner's National Priority Voucher (CNPV) for its Cytisinicline.The voucher is only available to nine programs in the program’s inaugural year. The program, announced in June, aims to reduce FDA assessment times to one to two months from the standard 10 to 12 months.Achieve Life Sciences’ Cytisinicline is indicated for nicotine e-cigarette or vaping cessation. “It's been nearly two decades since a new treatment option for smoking cessation was approved, and there are currently no treatment options for vaping cessation,” Achieve CEO Rick Stewart <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/17/3168544/0/en/Achieve-Life-Sciences-Receives-FDA-Commissioner-s-National-Priority-Voucher-for-Cytisinicline-for-Treatment-of-Nicotine-Dependence-for-E-cigarette-or-Vaping-Cessation.html">said</a>.In a mid-stage trial, participants treated with Cytisinicline were found to be 2.6 times more likely to quit using nicotine e-cigarettes or vapes compared to placebo. The FDA has agreed on a late-stage trial design that, together with the mid-stage data, would support an application for approval in vaping cessation.In September, the FDA accepted the company’s application for Cytisinicline as a treatment for smoking cessation. The agency is expected to decide on the application by June 20, 2026.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ACHV">ACHV stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:588/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_17_at_1_41_17_PM_png_6eea8f50e0.webp" alt="ACHV's Sentiment Meter and Message Volume as of 1:41 p.m. ET on Oct. 17, 2025 | Source: Stocktwits" width="588" height="62"><figcaption>ACHV's Sentiment Meter and Message Volume as of 1:41 p.m. ET on Oct. 17, 2025 | Source: Stocktwits</figcaption></figure>Other drugs awarded the voucher under the FDA program include Merck Group’s infertility treatment Pergoveris, Sanofi’s Type 1 diabetes therapy Teplizumab, Regeneron’s gene therapy DB-OTO for congenital deafness, and more.ACHV stock is up by 15% this year and down by about 20% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/kezar-life-sciences-stock-hit-with-downgrades-price-target-cuts/ch6sK5FR38U">Kezar Life Sciences Stock Hit With Downgrades And Price Target Cuts: Retail Keeps Hopes Alive</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration a 13 year old schoolboy holds single-use Vapes for Recycling in Kingston on Thames, England. (Photo by Peter Dazeley/Getty Images)

Achieve Life Sciences Stock Soars On Receiving FDA Voucher For Expediting Review Of Investigational Drug In Vaping Cessation

The program, announced in June, aims to reduce the time taken for FDA assessments from the standard 10 to 12 months to one to two months.

Equity

The program, announced in June, aims to reduce the time taken for FDA assessments from the standard 10 to 12 months to one to two months.


Shares of Revolution Medicines, Disc Medicine, and Regeneron Pharmaceuticals rose in after-hours trading on Thursday after the U.S. Food and Drug Administration (FDA) announced the first group of drugs selected for expedited review under its new National Priority Voucher pilot program.In after-hours trading on Thursday,&nbsp;<a href="https://stocktwits.com/symbol/RVMD">Revolution Medicines</a> jumped 9%,&nbsp;<a href="https://stocktwits.com/symbol/IRON">Disc Medicine</a> surged 17%, and&nbsp;<a href="https://stocktwits.com/symbol/REGN">Regeneron Pharmaceuticals</a> edged up 0.1%.FDA Names 9 Drugs For Accelerated ReviewThe FDA said nine products have been chosen for the fast-track review process, which shortens decision timelines from the usual 10–12 months to just one or two months once a complete application is filed.The selected drugs include Merck KGaA’s fertility treatment Pergoveris, Sanofi’s Type 1 diabetes therapy teplizumab, Regeneron’s gene therapy DB-OTO for congenital deafness, and ketamine for domestic manufacturing of a general anesthetic.&nbsp;Also on the list are Revolution Medicines’ RMC-6236 for pancreatic cancer, Disc Medicine’s bitopertin for porphyria, Achieve Life Sciences’ cytisinicline for nicotine vaping addiction, Dompe’s cenegermin-bkbj for blindness, and Augmentin XR for domestic manufacturing of a common antibiotic.FDA Commissioner Highlights Expedited Review EffortFDA Commissioner Marty Makary said the initiative could shorten FDA decision times from a year to "a matter of weeks” by moving promising or high-impact therapies to the front of the review line.Makary said some of the drugs selected for vouchers, including one that uses ketamine as a general anesthetic, will be manufactured in the United States. He described Regeneron’s DB-OTO, a gene therapy for congenital deafness, as “an exciting treatment,” noting that “some of these kids got normal hearing from this amazing treatment.”He added that this is just the first round of vouchers, with additional selections expected in the coming weeks.How Stocktwits Traders Reacted To FDA’s Fast-Track ListOn Stocktwits, retail sentiment toward Revolution Medicines was ‘extremely bullish’ with ‘extremely high’ message volume, while Disc Medicine saw ‘neutral’ sentiment amid similarly ‘extremely high’ activity, and Regeneron registered ‘neutral’ sentiment with ‘normal’ engagement levels.One&nbsp; user said they expect Regeneron shares to climb steadily, projecting the stock could reach the $800-$900 range within two years.&nbsp;<stembedurl>https://stocktwits.com/Iwannagofast1/message/632653980</stembedurl>Another bullish trader suggested Revolution Medicines could be an attractive takeover candidate, potentially fetching twice its current value.<stembedurl>https://stocktwits.com/ChessGM/message/632555600</stembedurl>So far this year, Revolution Medicines shares have gained 14%, Disc Medicine is up 17%, while Regeneron has declined 20%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the FDA (United States Food and Drug Administration) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program

The FDA’s new National Priority Voucher pilot helps with faster drug reviews, cutting timelines from nearly a year to weeks.

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.

ACHV
Achieve Life Sciences Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ACHV News

ACHVAchieve Life Sciences Inc.